AnaptysBio Inc.
Rating
Updated: Aug 25, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Ro...
Latest News
2 months ago · seekingalpha.com
AnaptysBio: The Royalty Waterfall Is About To ReverseAnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.
4 months ago · zacks.com
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
4 months ago · zacks.com
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
4 months ago · zacks.com
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowAfter losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
4 months ago · globenewswire.com
Anaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
4 months ago · globenewswire.com
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of DirectorsSAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.
5 months ago · zacks.com
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 months ago · zacks.com
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
5 months ago · globenewswire.com
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.
5 months ago · zacks.com
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseAnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ANAB